Description

ELTROXIN 50 MCG (1×120)

Indications

ELTROXIN 50 MCG is primarily indicated for the treatment of hypothyroidism, a condition characterized by insufficient production of thyroid hormones by the thyroid gland. It is also used in the management of goiter, a condition marked by an enlargement of the thyroid gland, and in the treatment of certain types of thyroid cancer. Additionally, ELTROXIN may be prescribed as a part of the post-surgical treatment regimen for patients who have undergone thyroidectomy.

Mechanism of Action

ELTROXIN contains levothyroxine sodium, a synthetic form of the thyroid hormone thyroxine (T4). The active ingredient mimics the natural hormone produced by the thyroid gland. Once administered, levothyroxine is converted into its active form, triiodothyronine (T3), in peripheral tissues. This hormone plays a critical role in regulating metabolism, influencing nearly every physiological process in the body, including growth, development, and energy metabolism. By restoring normal thyroid hormone levels, ELTROXIN helps to alleviate the symptoms associated with hypothyroidism, such as fatigue, weight gain, and depression.

Pharmacological Properties

Levothyroxine has a high oral bioavailability, with peak serum concentrations typically achieved within 2 to 4 hours after ingestion. The drug is extensively protein-bound, primarily to thyroxine-binding globulin (TBG), and has a long half-life of approximately 7 days, allowing for once-daily dosing. The pharmacokinetics of levothyroxine can be affected by various factors, including age, weight, and the presence of gastrointestinal disorders, which may alter absorption. ELTROXIN is metabolized mainly in the liver and kidneys, with its metabolites excreted through urine.

Contraindications

ELTROXIN is contraindicated in patients with known hypersensitivity to levothyroxine or any of the excipients in the formulation. It should not be used in cases of untreated adrenal insufficiency, as this may precipitate an adrenal crisis. Additionally, patients with thyrotoxicosis or those with acute myocardial infarction should avoid using this medication unless under careful medical supervision.

Side Effects

While ELTROXIN is generally well-tolerated, some patients may experience side effects. Common adverse reactions include headache, insomnia, nervousness, weight loss, increased appetite, and heat intolerance. More serious side effects may include palpitations, arrhythmias, and chest pain, particularly in patients with underlying cardiovascular conditions. Long-term over-treatment can lead to osteoporosis and increased fracture risk. It is essential for patients to report any unusual symptoms to their healthcare provider promptly.

Dosage and Administration

The dosage of ELTROXIN is individualized based on the patient’s age, weight, and clinical response. For adults with hypothyroidism, the typical starting dose is 1.6 mcg/kg body weight per day, which may be adjusted based on thyroid function tests. For elderly patients or those with cardiac conditions, a lower starting dose of 12.5 to 25 mcg may be recommended. ELTROXIN should be taken on an empty stomach, preferably 30 to 60 minutes before breakfast, to enhance absorption. Regular monitoring of thyroid function is essential to ensure optimal dosing and to avoid complications associated with over- or under-treatment.

Interactions

ELTROXIN may interact with various medications, which can affect its efficacy and safety. Drugs that may decrease the absorption of levothyroxine include antacids, calcium supplements, iron supplements, and certain proton pump inhibitors. Additionally, medications such as anticoagulants, antidepressants, and certain antiepileptics may require dosage adjustments when taken concurrently with ELTROXIN. Patients should inform their healthcare provider of all medications they are taking to avoid potential interactions.

Precautions

Before starting treatment with ELTROXIN, a thorough medical history and physical examination should be conducted. Patients with a history of cardiovascular disease, diabetes, or adrenal insufficiency require careful monitoring and potential dosage adjustments. It is also important to monitor thyroid function regularly to ensure that the patient remains within the therapeutic range. Pregnant women and those planning to become pregnant should discuss the risks and benefits of ELTROXIN use with their healthcare provider, as thyroid hormone levels can fluctuate during pregnancy.

Clinical Studies

Numerous clinical studies have demonstrated the efficacy and safety of levothyroxine in the treatment of hypothyroidism. A systematic review and meta-analysis published in the Journal of Clinical Endocrinology and Metabolism highlighted that levothyroxine therapy effectively normalizes thyroid hormone levels and improves quality of life in patients with hypothyroidism. Another study published in Thyroid Journal emphasized the importance of individualized dosing to achieve optimal therapeutic outcomes while minimizing side effects. These studies underscore the significance of ongoing research in optimizing treatment strategies for patients with thyroid disorders.

Conclusion

ELTROXIN 50 MCG is a vital medication for the management of hypothyroidism and other thyroid-related conditions. Its active ingredient, levothyroxine, effectively restores normal thyroid hormone levels, thereby alleviating symptoms and improving the quality of life for affected individuals. However, it is crucial for patients to adhere to prescribed dosages and maintain regular follow-up appointments with their healthcare provider to monitor thyroid function and adjust treatment as necessary. Understanding the pharmacological properties, potential side effects, and interactions of ELTROXIN is essential for safe and effective therapy.